Research map: Extended Half‐Life Recombinant Factor VIII Conjugated with Modifying Substances Does Not Affect Fibrin Clot Formation or Stability in Haemophilia A Blood Samples

Back to the article

Papers in this map

  1. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. · Björn Dahlbäck · 1993 · 1986 citations · Cited by this paper
  2. Real‐World Outcomes of Prophylaxis With rIX‐FP in Germany: A Prospective, Non‐Interventional Study in Haemophilia B · 2026 · Related
  3. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia · Marilyn J. Manco‐Johnson · 2007 · 1957 citations · Cited by this paper
  4. Gait Pattern at Different Speeds in Persons With Haemophilia · 2026 · Related
  5. Thrombin generation and fibrin clot structure · Alisa S. Wolberg · 2007 · 755 citations · Cited by this paper
  6. Accuracy of Factor VIII Assays for Measuring Damoctocog Alfa Pegol: A Comparative Analysis · 2026 · Related
  7. Fibrin Formation, Structure and Properties · John W. Weisel · 2017 · 750 citations · Cited by this paper
  8. Real‐World Effectiveness and Safety of Concizumab Prophylaxis in Hemophilia: Results From a National French Cohort · 2026 · Related
  9. Fibrin Clot Structure and Function · Anetta Undas · 2011 · 530 citations · Cited by this paper
  10. Seventh Åland Island Meeting on von Willebrand Disease · 2026 · Related
  11. Size and Density of Fibrin Fibers from Turbidity · Marcus E. Carr · 1978 · 331 citations · Cited by this paper
  12. The Analysis of the FIX‐inhibitor Risks Associated With the F9 Genotype in Patients With Haemophilia B Exposes the Involvement of Nonsense Mediated‐decay: Argentinean and International Series · 2026 · Related
  13. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A · Andreas Tiede · 2013 · 169 citations · Cited by this paper
  14. Predictors and Clinical Impact of Time to Diagnosis in Acquired Haemophilia A: An 11‐Year Retrospective Cohort Study · 2026 · Related
  15. The utility of thromboelastography in inherited and acquired bleeding disorders · Keiji Nogami · 2016 · 113 citations · Cited by this paper
  16. Successful Treatment of Heavy Menstrual Bleeding in a Woman With Mild Haemophilia A Using Efanesoctocog Alfa · 2026 · Related
  17. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process · Kazuya Hosokawa · 2011 · 97 citations · Cited by this paper
  18. Weight‐Bearing Lunge Test in Young Patients With Haemophilia and Limited Joint Damage: Reliability and Functional Associations for Ankle Assessment · 2026 · Related
  19. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? · Kenneth H. Lieuw · 2017 · 97 citations · Cited by this paper
  20. Real‐World Unmet Treatment Needs for Patients With Haemophilia: Results From the Global Adelphi Disease Specific Programme Database · 2026 · Related
  21. Extended Half-Life Factor VIII and Factor IX Preparations · Lukas Graf · 2018 · 79 citations · Cited by this paper
  22. Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease · Koichi Kaikita · 2019 · 78 citations · Cited by this paper
  23. Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A · Beatrice Nolan · 2015 · 74 citations · Cited by this paper
  24. Current and emerging factor VIII replacement products for hemophilia A · Lorraine A. Cafuir · 2017 · 61 citations · Cited by this paper
  25. Clot waveform analysis using CS ‐2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A · Tomoko Matsumoto · 2017 · 54 citations · Cited by this paper
  26. Clot stability as a determinant of effective factor VIII replacement in hemophilia A · Lilley Leong · 2017 · 45 citations · Cited by this paper
  27. Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip‐based flow chamber system · Kenichi Ogiwara · 2014 · 34 citations · Cited by this paper
  28. The biological efficacy profile of BAX 855, a PEG ylated recombinant factor VIII molecule · Leonard A. Valentino · 2014 · 32 citations · Cited by this paper
  29. Assessing the clinical severity of type 1 von Willebrand disease patients with a microchip flow‐chamber system · Keiji Nogami · 2016 · 31 citations · Cited by this paper
  30. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial · Elena Santagostino · 2019 · 27 citations · Cited by this paper
  31. Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand · Danijela Miković · 2013 · 26 citations · Cited by this paper
  32. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII‐deficient plasma, similar to the addition of factor VIII · Naruto Shimonishi · 2020 · 21 citations · Cited by this paper
  33. Impaired factor V–related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations · Naruto Shimonishi · 2023 · 13 citations · Cited by this paper
  34. The Utility of Total Thrombus‐Formation Analysis System (T‐ TAS ) in the Thrombosis and Hemostasis Field: A Scoping Review · Hassan Mansouritorghabeh · 2024 · 13 citations · Cited by this paper
  35. The Importance of Hemostasis on Long-Term Cardiovascular Outcomes in STEMI Patients—A Prospective Pilot Study · Aleksandra Karczmarska‐Wódzka · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)